Zelira Therapeutics Ltd. (AU:ZLD) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Zelira Therapeutics reports significant progress in Q3 FY2024, with key developments in their HOPE® Autism Spectrum Disorder program, including receiving the second tranche of SPV funding and advancing FDA trial processes. The company also secured a substantial R&D Tax Incentive refund and is on track to reformulate Zenivol® into a capsule, aiming for completion between late 2024 and early 2025.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.
